Only a few clinical studies have reported the effects of anti-TNF therapy on mitigating the PBC in patients with RA and reducing TNF-producing CD4 + T cells, serum transaminases, and immunoglobulins in patients with autoimmune hepatitis [41, 42]. Here, TNF is linked to primary biliary cholangitis.